Cytokeratin 16

GWB-3E815D

A synthetic peptide corresponding to residues near the N-terminus of human CK-16 was used as an immunogen.

WB: 1:2000 - 10 000IHC: 1:100 - 250ICC: 1:100 - 250FC: 1:10 - 100IP: 1:10 - 100. The human type I keratin 16 (CK16) is constitutively expressed in a number of complex epithelial tissues including skin but is better known for its induction under conditions favoring enhanced proliferation or abnormal differentiation including wound healing psoriasis and cancer (1). CK16 is expressed in suprabasal interfollicular epidermis in wound healing and other pathological conditions associated with hyperproliferation such as psoriasis and are induced when keratinocytes are cultured in vitro. However CK16 is also constitutively expressed in normal suprabasal mucosal and palmoplantar keratinocytes (2). Pachyonychia congenita (PC) is a group of inherited ectodermal dysplasias the characteristic phenotype being hypertrophic nail dystrophy. The PC-1 phenotype may be distinguished by the absence of the epidermal cysts found in PC-2 and it has been shown to be caused by mutations in either keratin K16 or its expression partner the K6a isoform of K6. Mutations in K16 have also been shown to cause a milder related phenotype focal non-epidermolytic palmoplantar keratoderma (3). 1. Paladini RD et al. Biochem Biophys Res Commun 215(2): 517-23 1995. 2. Shamsher MK et al. Hum Mol Genet 4(10):1875-81 19953. Smith FJ et al. BR J Dermatol 141(6):1010-6 19994. Manufactured under U. S. Patents No. 5 675 063 and 7 429 487